ReviewBMC pulmonary medicine2025
Allergic bronchopulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case series and literature review.
Review in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity disorder caused by Aspergillus sensitization, mostly associated with asthma, but occasionally seen in patients with chronic obstructive pulmonary disease (COPD). This study aimed to analyze the clinical features, treatment responses, and long-term follow-up of patients with ABPA-COPD overlap syndrome.
methodswe identified 6 cases of ABPA with underlying COPD from a cohort of ABPA in our hospital. We described symptoms, imaging findings, serology tests, pulmonary functions and treatment outcomes of these cases.
resultsFrom January 1st, 2013 to December 31th, 2024, 63 cases of ABPA were diagnosed in our hospital, of them 6 (9.52%) were found to have underlying COPD. The 6 patients were all male, aging from 63 to 89 years, with 5 having a smoking history. The presenting symptoms included persistent cough, sputum and exertional dyspnea. The blood total IgE was markedly elevated (1230-2951 KU/L), and all tested positive for A. fumigatus-specific IgE. Blood eosinophil count was 90-1610 cells/µl. CT revealed bronchiectasis (predominantly lower lobes) and emphysema in all cases. Four patients responded well to oral corticosteroids, while 2 required omalizumab for disease control. After follow-up for 1-4 years, 4 patients remained stable, 1 had recurrent exacerbations, and 1 died due to multi-organ failure.
conclusionsABPA should be considered in COPD patients with persistent or recurrent respiratory symptoms, higher blood eosinophils, particularly those with bronchiectasis on chest CT. ABPA represents a treatable trait in COPD patients. While corticosteroids remain the first-line therapy, treatment-resistant cases may benefit from biologic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.